InflaRx (IFRX) – Analysts’ Recent Ratings Updates
by Tristan Rich · The Markets DailySeveral brokerages have updated their recommendations and price targets on shares of InflaRx (NASDAQ: IFRX) in the last few weeks:
- 12/3/2025 – InflaRx had its “market perform” rating reaffirmed by analysts at Leerink Partners. They now have a $2.00 price target on the stock, down previously from $5.00.
- 12/3/2025 – InflaRx was downgraded by analysts at Leerink Partners from an “outperform” rating to a “market perform” rating. They now have a $2.00 price target on the stock, down previously from $5.00.
- 12/3/2025 – InflaRx was downgraded by analysts at Leerink Partnrs from a “strong-buy” rating to a “hold” rating.
- 12/1/2025 – InflaRx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/24/2025 – InflaRx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/17/2025 – InflaRx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/11/2025 – InflaRx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/11/2025 – InflaRx had its “outperform” rating reaffirmed by analysts at Raymond James Financial, Inc..
- 11/10/2025 – InflaRx had its price target raised by analysts at Guggenheim from $10.00 to $22.00. They now have a “buy” rating on the stock.
- 11/8/2025 – InflaRx was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
- 11/5/2025 – InflaRx had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
- 10/14/2025 – InflaRx had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Recommended Stories
- Five stocks we like better than InflaRx
- Do ETFs Pay Dividends? What You Need to Know
- Investors Were Dead Wrong About Box—This AI-Driven Comeback Just Proved It
- What Investors Need to Know to Beat the Market
- Can Alibaba’s Big Bets Pay Off After a Breakout Year?
- What is the Australian Securities Exchange (ASX)
- How Accenture’s OpenAI Partnership Turns AI Hype Into Profits